Reviewed,
UniProtKB/Swiss-Prot Q01668 (CAC1D_HUMAN)
Last modified
January 19, 2010.
Version 103.
History...
Clusters with 100%,
90%,
50% identity |
Documents (5) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Voltage-dependent L-type calcium channel subunit alpha-1D Alternative name(s): Voltage-gated calcium channel subunit alpha Cav1.3 Calcium channel, L type, alpha-1 polypeptide, isoform 2 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Complete proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 2161 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). |
| Subunit structure | Voltage-dependent calcium channels are multisubunit complexes, consisting of alpha-1, alpha-2, beta and delta subunits in a 1:1:1:1 ratio. The channel activity is directed by the pore-forming and voltage-sensitive alpha-1 subunit. In many cases, this subunit is sufficient to generate voltage-sensitive calcium channel activity. The auxiliary subunits beta and alpha-2/delta linked by a disulfide bridge regulate the channel activity. Interacts (via IQ domain) with CABP1 and CABP4 in a calcium independent manner By similarity. Interacts with RIMBP2 By similarity. |
| Subcellular location | |
| Tissue specificity | Expressed in pancreatic islets and in brain, where it has been seen in cerebral cortex, hippocampus, basal ganglia, habenula and thalamus. Expressed in the small cell lung carcinoma cell line SCC-9. No expression in skeletal muscle. Ref.4 |
| Domain | Each of the four internal repeats contains five hydrophobic transmembrane segments (S1, S2, S3, S5, S6) and one positively charged transmembrane segment (S4). S4 segments probably represent the voltage-sensor and are characterized by a series of positively charged amino acids at every third position. |
| Polymorphism | A change from seven to eight ATG trinucleotide repeats, resulting in an additional N-terminal methionine, has been found in a patient with non-insulin-dependent diabetes mellitus (NIDDM). |
| Sequence similarities | Belongs to the calcium channel alpha-1 subunit (TC 1.A.1.11) family. [View classification] |
Ontologies
| Keywords | |
|---|---|
| Biological process | Calcium transport Ion transport Transport |
| Cellular component | Membrane |
| Coding sequence diversity | Alternative splicing Polymorphism Triplet repeat expansion |
| Domain | Repeat Transmembrane |
| Ligand | Calcium |
| Molecular function | Calcium channel Ionic channel Voltage-gated channel |
| PTM | Disulfide bond Glycoprotein Phosphoprotein |
| Technical term | Complete proteome |
| Gene Ontology (GO) | |
| Biological process | calcium ion transport Inferred from direct assay. Source: UniProtKB transmembrane transportInferred from electronic annotation. Source: InterPro |
| Cellular component | voltage-gated calcium channel complex Inferred from direct assay. Source: UniProtKB |
| Molecular function | calcium ion binding Inferred from electronic annotation. Source: UniProtKB-KW dihydropyridine-sensitive calcium channel activityInferred from direct assay. Source: UniProtKB |
| Complete GO annotation... | |
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] Note: Additional isoforms seem to exist. | ||||||
| Isoform Neuronal-type (identifier: Q01668-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform Beta-cell-type (identifier: Q01668-2) The sequence of this isoform differs from the canonical sequence as follows: 373-392: MNDAMGFELPWVYFVSLVIF → VNDAIGWEWPWVYFVSLIIL 493-493: C → WCWWRRRGAAKAGPSGCRRWG |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 2161 | 2161 | Voltage-dependent L-type calcium channel subunit alpha-1D | PRO_0000053933 | |||||
Regions | |||||||||
| Topological domain | 1 – 126 | 126 | Cytoplasmic Potential | ||||||
| Transmembrane | 127 – 145 | 19 | S1 of repeat I Potential | ||||||
| Topological domain | 146 – 163 | 18 | Extracellular Potential | ||||||
| Transmembrane | 164 – 183 | 20 | S2 of repeat I Potential | ||||||
| Topological domain | 184 – 195 | 12 | Cytoplasmic Potential | ||||||
| Transmembrane | 196 – 214 | 19 | S3 of repeat I Potential | ||||||
| Topological domain | 215 – 235 | 21 | Extracellular Potential | ||||||
| Transmembrane | 236 – 254 | 19 | S4 of repeat I Potential | ||||||
| Topological domain | 255 – 273 | 19 | Cytoplasmic Potential | ||||||
| Transmembrane | 274 – 293 | 20 | S5 of repeat I Potential | ||||||
| Topological domain | 294 – 381 | 88 | Extracellular Potential | ||||||
| Transmembrane | 382 – 406 | 25 | S6 of repeat I Potential | ||||||
| Topological domain | 407 – 523 | 117 | Cytoplasmic Potential | ||||||
| Transmembrane | 524 – 543 | 20 | S1 of repeat II Potential | ||||||
| Topological domain | 544 – 558 | 15 | Extracellular Potential | ||||||
| Transmembrane | 559 – 577 | 19 | S2 of repeat II Potential | ||||||
| Topological domain | 578 – 585 | 8 | Cytoplasmic Potential | ||||||
| Transmembrane | 586 – 604 | 19 | S3 of repeat II Potential | ||||||
| Topological domain | 605 – 614 | 10 | Extracellular Potential | ||||||
| Transmembrane | 615 – 633 | 19 | S4 of repeat II Potential | ||||||
| Topological domain | 634 – 652 | 19 | Cytoplasmic Potential | ||||||
| Transmembrane | 653 – 673 | 21 | S5 of repeat II Potential | ||||||
| Topological domain | 674 – 727 | 54 | Extracellular Potential | ||||||
| Transmembrane | 728 – 752 | 25 | S6 of repeat II Potential | ||||||
| Topological domain | 753 – 886 | 134 | Cytoplasmic Potential | ||||||
| Transmembrane | 887 – 905 | 19 | S1 of repeat III Potential | ||||||
| Topological domain | 906 – 921 | 16 | Extracellular Potential | ||||||
| Transmembrane | 922 – 941 | 20 | S2 of repeat III Potential | ||||||
| Topological domain | 942 – 953 | 12 | Cytoplasmic Potential | ||||||
| Transmembrane | 954 – 972 | 19 | S3 of repeat III Potential | ||||||
| Topological domain | 973 – 978 | 6 | Extracellular Potential | ||||||
| Transmembrane | 979 – 998 | 20 | S4 of repeat III Potential | ||||||
| Topological domain | 999 – 1017 | 19 | Cytoplasmic Potential | ||||||
| Transmembrane | 1018 – 1037 | 20 | S5 of repeat III Potential | ||||||
| Topological domain | 1038 – 1127 | 90 | Extracellular Potential | ||||||
| Transmembrane | 1128 – 1148 | 21 | S6 of repeat III Potential | ||||||
| Topological domain | 1149 – 1205 | 57 | Cytoplasmic Potential | ||||||
| Transmembrane | 1206 – 1224 | 19 | S1 of repeat IV Potential | ||||||
| Topological domain | 1225 – 1239 | 15 | Extracellular Potential | ||||||
| Transmembrane | 1240 – 1259 | 20 | S2 of repeat IV Potential | ||||||
| Topological domain | 1260 – 1266 | 7 | Cytoplasmic Potential | ||||||
| Transmembrane | 1267 – 1288 | 22 | S3 of repeat IV Potential | ||||||
| Topological domain | 1289 – 1313 | 25 | Extracellular Potential | ||||||
| Transmembrane | 1314 – 1333 | 20 | S4 of repeat IV Potential | ||||||
| Topological domain | 1334 – 1352 | 19 | Cytoplasmic Potential | ||||||
| Transmembrane | 1353 – 1372 | 20 | S5 of repeat IV Potential | ||||||
| Topological domain | 1373 – 1439 | 67 | Extracellular Potential | ||||||
| Transmembrane | 1440 – 1464 | 25 | S6 of repeat IV Potential | ||||||
| Topological domain | 1465 – 2161 | 697 | Cytoplasmic Potential | ||||||
| Repeat | 113 – 409 | 297 | I | ||||||
| Repeat | 509 – 755 | 247 | II | ||||||
| Repeat | 873 – 1155 | 283 | III | ||||||
| Repeat | 1192 – 1467 | 276 | IV | ||||||
| Calcium binding | 1493 – 1504 | 12 | By similarity | ||||||
| Region | 429 – 446 | 18 | Binding to the beta subunit By similarity | ||||||
| Region | 1075 – 1165 | 91 | Dihydropyridine binding By similarity | ||||||
| Region | 1420 – 1486 | 67 | Dihydropyridine binding By similarity | ||||||
| Region | 1432 – 1475 | 44 | Phenylalkylamine binding By similarity | ||||||
| Compositional bias | 1 – 7 | 7 | Poly-Met | ||||||
| Compositional bias | 653 – 659 | 7 | Poly-Leu | ||||||
| Compositional bias | 827 – 838 | 12 | Poly-Glu | ||||||
Sites | |||||||||
| Site | 364 | 1 | Calcium ion selectivity and permeability By similarity | ||||||
| Site | 705 | 1 | Calcium ion selectivity and permeability By similarity | ||||||
| Site | 1101 | 1 | Calcium ion selectivity and permeability By similarity | ||||||
| Site | 1406 | 1 | Calcium ion selectivity and permeability By similarity | ||||||
Amino acid modifications | |||||||||
| Modified residue | 1475 | 1 | Phosphoserine; by PKA Potential | ||||||
| Modified residue | 1905 | 1 | Phosphoserine Ref.5 | ||||||
| Glycosylation | 155 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 225 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 329 | 1 | N-linked (GlcNAc...) Potential | ||||||
Natural variations | |||||||||
| Alternative sequence | 373 – 392 | 20 | MNDAM…SLVIF → VNDAIGWEWPWVYFVSLIIL in isoform Beta-cell-type. | VSP_000913 | |||||
| Alternative sequence | 493 | 1 | C → WCWWRRRGAAKAGPSGCRRW G in isoform Beta-cell-type. | VSP_000914 | |||||
| Natural variant | 1 | 1 | M → MM in a NIDDM patient. Ref.3 | VAR_001497 | |||||
| Natural variant | 2097 | 1 | D → N: dbSNP rs41276455. | VAR_061103 | |||||
Experimental info | |||||||||
| Sequence conflict | 576 | 1 | S → T in BAA07804. Ref.3 | ||||||
| Sequence conflict | 637 | 1 | S → C in AAA58402. Ref.1 | ||||||
| Sequence conflict | 650 | 1 | I → S in AAA58402. Ref.1 | ||||||
| Sequence conflict | 918 | 1 | I → T in BAA07804. Ref.3 | ||||||
| Sequence conflict | 960 | 1 | M → I in BAA07804. Ref.3 | ||||||
| Sequence conflict | 1289 – 1290 | 2 | Missing in BAA07804. Ref.3 | ||||||
| Sequence conflict | 1346 | 1 | S → F in AAA58402. Ref.1 | ||||||
| Sequence conflict | 1433 | 1 | Y → H in AAA58402. Ref.1 | ||||||
Sequences
| ||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype." Williams M.E., Feldman D.H., McCue A.F., Brenner R., Velicelebi G., Ellis S.B., Harpold M.M. Neuron 8:71-84(1992) [PubMed: 1309651] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM NEURONAL-TYPE). Tissue: Neuroblastoma. |
| [2] | "Cloning of the alpha 1 subunit of a voltage-dependent calcium channel expressed in pancreatic beta cells." Seino S., Chen L., Seino M., Blondel O., Takeda J., Johnson J.H., Bell G.I. Proc. Natl. Acad. Sci. U.S.A. 89:584-588(1992) [PubMed: 1309948] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-CELL-TYPE). Tissue: Pancreatic islet. |
| [3] | "The structures of the human calcium channel alpha 1 subunit (CACNL1A2) and beta subunit (CACNLB3) genes." Yamada Y., Masuda K., Li Q., Ihara Y., Kubota A., Miura T., Nakamura K., Fujii Y., Seino S., Seino Y. Genomics 27:312-319(1995) [PubMed: 7557998] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM BETA-CELL-TYPE), VARIANT MET-1 INS. |
| [4] | "Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma." Oguro-Okano M., Griesmann G.E., Wieben E.D., Slaymaker S.J., Snutch T.P., Lennon V.A. Mayo Clin. Proc. 67:1150-1159(1992) [PubMed: 1335101] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 747-1039, TISSUE SPECIFICITY. Tissue: Lung carcinoma. |
| [5] | "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Cell 127:635-648(2006) [PubMed: 17081983] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1905, MASS SPECTROMETRY. Tissue: Epithelium. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |
|---|---|
| EMBL GenBank DDBJ | M76558 mRNA. Translation: AAA58402.1. M83566 mRNA. Translation: AAA35629.1. D43747 Genomic DNA. Translation: BAA07804.1. |
| IPI | IPI00009008. IPI00216354. |
| PIR | JH0564. |
| RefSeq | NP_000711.1. NP_001122311.1. NP_001122312.1. |
| UniGene | Hs.476358 |
3D structure databases | |
| SMR | Q01668. Positions 124-201, 1199-1468, 1600-1628. |
| ModBase | Search... |
Protein-protein interaction databases | |
| STRING | Q01668. |
PTM databases | |
| PhosphoSite | Q01668. |
Proteomic databases | |
| PRIDE | Q01668. |
Genome annotation databases | |
| Ensembl | ENST00000350061; ENSP00000288133; ENSG00000157388; Homo sapiens. [Genome view] |
| GeneID | 776. |
| KEGG | hsa:776. |
| UCSC | uc003dgu.2. human. uc003dgv.2. human. |
Organism-specific databases | |
| CTD | 776. |
| GeneCards | GC03P053504. |
| H-InvDB | HIX0030870. |
| HGNC | HGNC:1391. CACNA1D. |
| HPA | CAB009777. HPA020215. |
| MIM | 114206. gene. |
| PharmGKB | PA84. |
| GenAtlas | Search... |
Phylogenomic databases | |
| eggNOG | prNOG08933. |
| HOVERGEN | Q01668. |
| OMA | QIQDIAN. |
| PhylomeDB | Q01668. |
Enzyme and pathway databases | |
| Reactome | REACT_1505. Integration of energy metabolism. REACT_15380. Diabetes pathways. |
Gene expression databases | |
| ArrayExpress | Q01668. |
| Bgee | Q01668. |
| CleanEx | HS_CACNA1D. |
| Genevestigator | Q01668. |
| GermOnline | ENSG00000157388. Homo sapiens. |
Family and domain databases | |
| InterPro | IPR011992. EF-hand-like_dom. IPR005821. Ion_trans. IPR005452. LVDCC_a1dsu. IPR014873. VDCC_a1su_IQ. IPR005446. VDCC_L_a1su. IPR002077. VDCCAlpha1. [Graphical view] |
| Gene3D | G3DSA:1.10.238.10. EF-Hand_type. 1 hit. |
| PANTHER | PTHR10037:SF48. LVDCCAlpha1D. 1 hit. |
| Pfam | PF08763. Ca_chan_IQ. 1 hit. PF00520. Ion_trans. 4 hits. [Graphical view] |
| PRINTS | PR00167. CACHANNEL. PR01630. LVDCCALPHA1. PR01636. LVDCCALPHA1D. |
| ProtoNet | Search... |
Other Resources | |
| DrugBank | DB00661. Verapamil. |
| NextBio | 3136. |
| SOURCE | Search... |
Entry information
| Entry name | CAC1D_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q01668 Secondary accession number(s): Q13916, Q13931, Q9UDC3 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation project | HPI (Human Proteome Initiative) | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 3 Human chromosome 3: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| SIMILARITY comments Index of protein domains and families |

Clusters with


